EXTENDED REPORT

EULAR recommendations for women’s health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome

L Andreoli,1,2 G K Bertsias,3 N Agmon-Levin,4,5 S Brown,6 R Cervera,7 N Costedoat-Chalumeau,8,9 A Doria,10 R Fischer-Betz,11 F Forger,12 M F Moraes-Fontes,13 M Khamashta,14,15 J King,16 A Lojaco,1,17 F Marchiori,18 P L Meroni,19 M Mosca,20 M Motta,21 M Ostensen,22 C Pammilia,23 L Rairo,24 M Schneider,11 E Svenungsson,25 M Tektonidou,26 S Yavuz,27 D Boumpas,28,29 A Tincani1,2

ABSTRACT

Objectives Develop recommendations for women’s health issues and family planning in systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS).

Methods Systematic review of evidence followed by modified Delphi method to compile questions, elicit expert opinions and reach consensus.

Results Family planning should be discussed as early as possible after diagnosis. Most women can have successful pregnancies and measures can be taken to reduce the risks of adverse maternal or fetal outcomes. Risk stratification includes disease activity, autoantibody profile, previous vascular and pregnancy morbidity, hypertension and the use of drugs (emphasis on benefits from hydroxychloroquine and antplatelets/anticoagulants). Hormonal contraception and menopause replacement therapy can be used in patients with stable/inactive disease and low risk of thrombosis. Fertility preservation with gonadotropin-releasing hormone analogues should be considered prior to the use of alkylating agents. Assisted reproduction techniques can be safely used in patients with stable/inactive disease; patients with positive antiphospholipid antibodies/APS should receive anticoagulation and/or low-dose aspirin. Assessment of disease activity, renal function and serological markers is important for diagnosing disease flares and monitoring for obstetrical adverse outcomes. Fetal monitoring includes Doppler ultrasonography and fetal biometry, particularly in the third trimester, to screen for placental insufficiency and small for gestational age fetuses. Screening for gynaecological malignancies is similar to the general population, with increased vigilance for cervical premalignant lesions if exposed to immunosuppressive drugs. Human papillomavirus immunisation can be used in women with stable/inactive disease.

Conclusions Recommendations for women’s health issues in SLE and/or APS were developed using an evidence-based approach followed by expert consensus.

INTRODUCTION

Systemic lupus erythematosus (SLE) and the antiphospholipid syndrome (APS), SLE-associated or primary APS, affect mostly women of childbearing age. Several ‘unmet needs’ in the management of reproductive and other women’s health issues may impact on personal relationships and the decision to have children. Because of earlier recognition of disease and advances in medical treatment, family planning has gained greater importance. Concerns include the effect of pregnancy on maternal disease, the impact of disease activity on fetal health and the safety of medications during pregnancy and breast feeding. Assessment of fertility and feasibility of assisted reproduction techniques (ARTs), use of contraception, management of menopause and surveillance against malignancies need to be addressed. We gathered a multidisciplinary panel of experts to develop evidence-based recommendations on the management of family planning and women’s health issues in SLE and/or APS.

METHODS

We followed the European League Against Rheumatism (EULAR) standardised operating procedures1 and the Appraisal of Guidelines Research and Evaluation instrument. Through a Delphi-based approach, the committee selected 12 research questions further edited for systematic literature review (see online supplementary table S1). We searched PubMed using arrays of relevant terms; all English-language publications up to December 2014 were considered. A hand search was also performed in October 2015. Retrieved items were refined based on abstract, full-text content and number of included patients. A detailed presentation of the literature review is given in the online supplementary table S2. Evidence was categorised based on the design and validity of available studies and the strength of the statements was graded (see online supplementary table S3). After rounds of
2. Contraceptive measures

2.1 Women with SLE should be counselled about the use of effective contraceptive measures (oral contraceptives, subcutaneous implants, IUD), based on their disease activity and thrombotic risk (particularly aPL status). IUD can be offered to all the patients with SLE and/or APS free of any gynaecological contraindication (1/A).

2.2 In patients with stable/inactive SLE and negative aPL, combined hormonal contraceptives can be considered (1/A). In women with positive aPL with or without definite APS, hormonal contraception (with progesterone only) must be carefully weighed against the risk of thrombosis (2/B).

3. Risk factors for reduced fertility

Women with SLE who wish to plan a pregnancy should be counselled about fertility issues, especially the adverse outcomes associated with increasing age and the use of alkylating agents (1/A). Treatment with alkylating agents should be balanced against the risk of ovarian dysfunction.

4. Preservation of fertility

Fertility preservation methods, especially GnRH analogues, should be considered for all menstruating women with SLE who are going to receive alkylating agents (2/B).

5. Assisted reproduction techniques

5.1 Assisted reproduction techniques, such as ovulation induction treatments and in vitro fertilisation protocols, can be safely used in patients with SLE and/or APS (2/C).

5.2 Patients with positive aPL/APS should receive anticoagulation (at the dosage as would be recommended during pregnancy) and/or low-dose aspirin (3/D).

6. Predictive biomarkers for maternal disease activity in SLE pregnancy

In pregnant women with SLE, assessment of disease activity (1/A)—including renal function parameters (2/B) and serological markers (serum C3/C4, anti-dsDNA titre) (2/B)—is recommended to monitor for obstetrical adverse outcomes and disease flares.

7. Pregnancy monitoring

7.1 Women with SLE and/or APS should undergo supplementary fetal surveillance with Doppler ultrasonography and biometric parameters, particularly in the third trimester to screen for placental insufficiency and small for gestational age fetuses (3/D).

7.2 Fetal echocardiography is recommended in cases of suspected fetal dysrhythmia or myocarditis, especially in patients with positive anti-Ro/SSA and/or anti-La/SSB antibodies (2/C).

8. Drugs for the prevention and management of SLE flares during pregnancy

8.1 HCQ (1/B), oral glucocorticoids, azathioprine, ciclosporin A and tacrolimus (all 3/C) can be used to prevent or manage SLE flares during pregnancy.

8.2 Moderate-to-severe flares can be managed with additional strategies, including glucocorticoids intravenous pulse therapy, intravenous immunoglobulin and plasmapheresis (all 3/C).

8.3 Mycophenolic acid, cyclophosphamide, leflunomide and methotrexate should be avoided.

9. Adjunct treatment during pregnancy

9.1 HCQ is recommended preconceptionally and throughout pregnancy for patients with SLE (2/B).

9.2 Women with SLE at risk of pre-eclampsia (especially those with lupus nephritis or positive aPL) should receive LDA (2/C). In women with SLE-associated APS or primary APS, combination treatment with LDA and heparin is recommended to decrease the risk of adverse pregnancy outcomes (1/A).

9.3 Supplementation with calcium, vitamin D and folic acid should be offered as in the general population (−/D). Measuring blood vitamin D levels should be considered after pregnancy is confirmed (−/D).

10. Menopause and HRT

HRT can be used for the management of severe vasomotor menopausal manifestations in SLE women with stable/inactive disease and negative aPL (1/A). The use of HRT in patients with positive APS should be carefully weighed against the risk of thrombosis and cardiovascular disease (−/D).

11. Screening for malignancies

Women with SLE and/or APS should undergo screening for malignancies similar to the general population (−/D). Women with SLE, especially those exposed to immunosuppressive drugs, are at higher risk of cervical premalignant lesions and should be monitored with vigilance (2/B).

12. HPV vaccination

HPV immunisation can be considered in women with SLE and/or APS and stable/inactive disease (3/D).

For each statement or item, the LoE (range 1–3) and the GoR (range A–D) is given in parentheses (refer to online supplementary table S1). In the right-hand columns, the LoE among experts is reported as mean (SD) and median (IQR) values. A score of 10 represents the highest level of agreement.

*aPL and APS are defined according to the updated international consensus criteria. For aPL assays, please see the footnotes of table 2.

† The substatement on fetal echo in women with SLE/APS and positive anti-Ro/La is rated with LoE=2 (ie, sufficient evidence for the association between anti-Ro/La and congenital heart block) but GoR=C due to lack of strong evidence for the clinical implications of this association, namely for the efficacy of interventions.

anti-dsDNA, anti-double-stranded DNA antibodies; aPL, antiphospholipid antibodies; GnRH, gonadotropin-releasing hormone; GoR, grade of recommendation; HCQ, hydroxychloroquine; HPV, human papillomavirus; HRT, hormone replacement therapy; IUD, intrauterine devices; LDA, low-dose aspirin; LoA, level of agreement; LoE, level of evidence.
Recommendations

Preconception counselling and risk stratification

Assessment of risk factors for adverse maternal and fetal outcomes in pregnant women with SLE and/or APS is crucial for preconception counselling and implementing appropriate preventive strategies and patient-tailored monitoring plan before and during pregnancy (Table 2).

In SLE women (with or without APS), prematurity, pre-eclampsia and eclampsia/Hemolysis, Elevated Liver enzyme levels, Low Platelet count (HELLP) rates approximate 25–35%, 10–15% and 1.0–1.5%, respectively.19 24 25 44 51 52 In APS women (primary or SLE-related), the respective frequencies approximate 25–35%, 10–20% and 3.0–5.0%, 28 29 33 54

During pregnancy, risk factors associated with adverse outcomes include active/flaring SLE (OR 12.7 for pre-eclampsia/eclampsia),53 19.0 for emergency caesarean section; 56 3.0 for early fetal loss;20 5.5 for preterm delivery),21 19 active nephritis (OR 5.3 for any adverse maternal outcome),57 hypertension (OR 4.8–7.3 for pre-eclampsia),52 relative risk (RR) 1.8 for preterm birth)52 and use of glucocorticoids, especially at maintenance dose ≥10–20 mg/day of prednisone equivalent (OR 3.5 for preterm birth).58 59 Discontinuation of hydroxychloroquine (HCQ) is related to an increased risk for SLE exacerbations during pregnancy,24 33 56 and a single placebo-controlled study has suggested a beneficial effect of HCQ on maternal disease activity during pregnancy.60

Contraceptive measures

Women with SLE and/or APS should be counselled about contraception, especially for the prevention of unwanted pregnancies during high disease activity periods and intake of teratogenic drugs. Effective contraceptive measures should be

Table 2 Checklist of parameters to be considered for preconception counselling and risk stratification in women with systemic lupus erythematosus (SLE) and/or antiphospholipid syndrome (APS)

<table>
<thead>
<tr>
<th>Disease-related risk factors</th>
<th>Prognostic implications</th>
</tr>
</thead>
<tbody>
<tr>
<td>SLE activity/flare (in the last 6–12 months or at conception)</td>
<td>Increased risk for (i) maternal disease activity (RR 2.1 for subsequent flare during pregnancy and puerperium);14 (ii) hypertensive complications (OR 1.8 for PE);15 (iii) fetal mortality and morbidity (OR 5.7 for pregnancy loss,16 3.5 for IUGR)17 6.5 for preterm delivery)18 19 15 17–22</td>
</tr>
<tr>
<td>Lupus nephritis (history or active at conception)</td>
<td>Strong predictor of poor maternal (RR 9.0 for renal failure during/after pregnancy)20 and fetal outcome(s) (OR 7.3 for fetal loss and 18.9 for preterm delivery)21 22</td>
</tr>
<tr>
<td>Serological (serum C3/C4, anti-dsDNA titre) activity</td>
<td>Increased risk for maternal SLE flares during pregnancy (OR 5.3)23 and pregnancy loss24 25 26 27</td>
</tr>
<tr>
<td>Previous adverse pregnancy outcome(s)</td>
<td>APS: increased risk for pregnancy complications28–30</td>
</tr>
<tr>
<td>History of vascular thrombosis</td>
<td>APS: increased risk (ORs ranging 3.6–12.7) for pregnancy morbidity31</td>
</tr>
<tr>
<td>SLE diagnosis</td>
<td>APS: increased risk (OR 6.9) for pregnancy morbidity32</td>
</tr>
<tr>
<td>aPL profile†</td>
<td>SLE: strong predictor of adverse maternal and fetal outcomes19 25 27 33 34 especially for patients with persistent moderate-to-high aPL titre, LA and multiple aPL positivity (high-risk aPL profile)35 APS: high-risk aPL profile correlates with increased risk of maternal vascular thrombotic events during pregnancy (OR 12.1),35 (pre-)eclampsia (OR 2.3),36 37 APS-related pregnancy morbidity (OR 9.2),31 IUGR (OR 4.7),38 preterm birth39</td>
</tr>
<tr>
<td>Anti-RoSSA, anti-LaSSB antibodies</td>
<td>Linked to development of neonatal lupus, including a low risk (0.7–2%) for CHB (especially if moderate-to-high anti-Ro titre);40–41 weak association with other pregnancy complications44</td>
</tr>
<tr>
<td>End-stage organ damage and associated comorbidities</td>
<td>45 46</td>
</tr>
<tr>
<td>General risk factors</td>
<td>47</td>
</tr>
<tr>
<td>Maternal age</td>
<td>48</td>
</tr>
<tr>
<td>Arterial hypertension</td>
<td>Increased risk for pregnancy loss (OR 2.4,33 RR 2.9),48 preterm birth18 24 27 and IUGR (OR 6.8)15</td>
</tr>
<tr>
<td>Diabetes mellitus</td>
<td>49</td>
</tr>
<tr>
<td>Overweight/obesity</td>
<td>50</td>
</tr>
<tr>
<td>Thyroid disease</td>
<td>51</td>
</tr>
<tr>
<td>Nicotine and alcohol use</td>
<td>28</td>
</tr>
<tr>
<td>Immunisations§</td>
<td>§If negative serology, evaluate whether immunisations can be performed prior to pregnancy (eg, rubella).</td>
</tr>
</tbody>
</table>

*Diagnosed by validated SLE activity indices and/or physician judgement.
†Evaluated by renal function tests (serum creatinine, blood urea nitrogen) and urinalysis (proteinuria urine sediment).
‡Includes LA, aCL IgG/IgM, a2GPI IgG/IgM. The level of positivity of aCL and a2GPI antibodies (low vs medium–high) should be defined according to the single assay’s characteristics.
§If negative serology, evaluate whether immunisations can be performed prior to pregnancy (eg, rubella).
β12 months
478

RESULTS AND DISCUSSION

Scope and overarching principles

These recommendations have been devised with the intention of helping physicians involved in the care of patients with SLE and/or APS and facilitating physician–patient communication. They recognise an implicit need for change in the mindset of health professionals, shifting from caution against pregnancy towards embrace ment of pregnancy. Accordingly, family planning should be discussed from the first physician–patient encounter and reinforced thereafter. Health professionals should support the patient and her family in their decisions regarding family planning by discussing individual pregnancy risks. Reports on the long-term follow-up of SLE and/or APS offspring are few,7–10 showing a reassuring picture on the health conditions of the children, with the exception of some cases of neurodevelopmental alterations11–13 that need further confirmation before they are linked to maternal disease.

discussions, the committee arrived at 12 final statements (Table 1). Each member rated her/his agreement with each statement.
discussed with the patient by weighing the individual risk factors, including general (hypertension, obesity, tobacco use, family history of hormonal-dependent cancers) and disease-related risk factors, particularly disease activity and thrombotic risk (emphasis on antiphospholipid antibodies (aPLs)).

The intrauterine device (IUD) can be offered to all patients unless there is a gynaecological contraindication. Copper IUD can be used in any patient, while levonorgestrel-containing IUD should be considered only if the benefits of the released hormone (such as the reduction of excessive menstrual bleeding due to anticoagulation) outweigh the risk of thrombosis.

The safety of the combined (oestrogen plus progesterin) and progestin-only pill in SLE patients with inactive or stable active SLE and negative aPL has been demonstrated in randomised controlled trials (RCTs). In women with positive aPL (with or without definite APS), contraception with combined hormones (oral pill, vaginal ring, transdermal patch) should be discouraged. In young women with myocardial infarction or ischaemic stroke and positive lupus anticoagulant, the use of the combined pill increased the risk of arterial events compared with non-users. In fully anticoagulated patients carrying a low-risk aPL profile, oestrogens might be considered for persistent gynaecological disorders not otherwise managed. Compounds containing progestin only (pill, subcutaneous depot injections) are suitable for these women, although their use should be weighed against the risk of thrombosis. Progestin-only emergency contraception is not contraindicated in patients with SLE and/or APS.

Risk factors for reduced fertility
Few studies have assessed fertility in women with SLE and/or APS by means of hormonal levels (including the anti-Müllerian hormone) or antral follicle count (examined by ultrasound). There is no concrete evidence that the disease per se decreases fertility. However, active disease, especially lupus nephritis, and the use of immunosuppressive drugs may negatively impact on fertility. Alkylating agents such as cyclophosphamide (CYC) may cause menstrual irregularities and premature ovarian failure (POF), which is age- and dosage dependent.

Similar to the general population, women with SLE and/or APS should be counselled on fertility issues, especially on the negative impact of increasing age (general tendency to postpone childbearing) and certain lifestyle exposures (tobacco use, alcohol consumption). In non-life-threatening disease, treatment with alkylating agents should be balanced against the risk of ovarian dysfunction; rather, less gonadotoxic regimens should be considered. In the presence of multiple risk factors for impaired fertility, ovarian reserve may be assessed in patients with SLE at a younger age than recommended for the general population.

Fertility preservation
Limited data are available on fertility preservation methods in menstruating women with SLE who require treatment with alkylating agents. Cryopreservation of ovarian tissue or oocytes/embryos are poorly investigated options and require specialised centres, which may not be easily accessible. The most extensively studied method for POF prevention in patients with SLE involves gonadotropin-releasing hormone analogues (GnRH-a), with a good safety and efficacy profile (RR 0.12). GnRH-a have been efficacious in patients with cancer. GnRH-a are likely to protect against POF, but there are no data on subsequent pregnancies in patients with SLE. They can cause menopausal-like symptoms, which are fully reversible upon discontinuation. A study in childhood-onset patients with SLE aged <21 years suggested that GnRH-a should be administered 22 days before CYC is started or continued. It is nevertheless recommended to start the GnRH-a prior to or concomitantly to initiation of the alkylating agent.

Assisted reproduction techniques
Evidence on the efficacy and safety of ARTs (ovulation induction therapy and in vitro fertilisation) in women with SLE and/or APS comes from observational studies. Efficacy in terms of pregnancy rate is comparable with that in the general population (up to 30%). ARTs are generally safe if the patient has quiescent disease and is on appropriate antithrombotic treatment if aPL positive. Although it is challenging to define a single protocol, some general measures for prophylaxis in aPL-positive women undergoing ovarian stimulation can be suggested. The type (low-dose aspirin (LDA); low molecular weight heparin (LMWH)) and dosage (prophylactic vs full anticoagulant) of antithrombotic treatment should be recommended as during pregnancy according to the individual risk profile. LDA should be stopped three days before egg retrieval and resumed the following day. Patients taking LMWH should stop it at least 12 hours prior to the procedure and resume it the very same day as long as there is no bleeding. Patients with positive aPL who are not taking LDA during the ovarian stimulation period should start LDA on the day of the embryo transfer, usually in combination with LMWH (which will be continued during pregnancy).

Ovarian hyperstimulation syndrome can be avoided by milder hormonal stimulation or GnRH antagonist protocol. The use of the ‘natural cycle’ method is another option, although associated with a lower rate of induced pregnancy. The ART induction protocol should be tailored to the individual patient, balancing the safety and effectiveness of the procedure.

Predictive biomarkers for maternal disease activity in SLE pregnancy
Active SLE during pregnancy, assessed by validated disease activity indices and/or physician global assessment, is associated with increased risk for maternal and/or fetal complications (see also paragraph on Preconception counselling and risk stratification). Pregnancy-specific SLE activity indices have been developed and validated for their sensitivity in detecting changes in disease activity and diagnosing flares (see online supplementary table S4). Physicians should be aware of pregnancy physiological changes that can resemble SLE symptoms and signs. Renal activity correlates with adverse pregnancy outcomes and should be monitored by means of urine protein excretion, urine sediment analysis (glomerular haematuria, urinary casts) and serum creatinine level/glomerular filtration rate.

Serological markers are useful in monitoring SLE activity and in the differentiation between disease exacerbation (declining serum C3/C4 levels (even within the normal range) and/or increasing anti-double stranded DNA titres) and pre-eclampsia. Smaller increases in serum C3 levels from pregnancy onset to the second or third trimester as well as serological activity (as defined above) that develops during pregnancy, especially in the context of clinical SLE activity, have been associated with increased risk for pregnancy loss, intrauterine growth restriction (IUGR) and preterm birth.
Pregnancy monitoring

Pregnant women with SLE and/or APS should follow the local protocols applied to pregnancies at high risk for hypertensive disorders and/or placental insufficiency, adjusting the frequency and modality of fetal surveillance according to the maternal and/or fetal status (Box 1). Fetal surveillance based on biometric and Doppler findings during the third trimester, and particularly the distinction between early and late IUGR, helps to better tailor the time of delivery and reduce perinatal morbidity and mortality.93–97 Umbilical and uterine arteries Doppler sonography at 20–24 weeks has good negative predictive value but modest positive predictive value (especially in the absence of biometric signs of fetal growth restriction later in pregnancy) for placental-associated pregnancy disorders such as pre-eclampsia and IUGR. The mode (vaginal vs caesarean section) and timing of delivery are influenced by maternal (hypertensive disorders, anticoagulation status) as well as fetal conditions during pregnancy.

Fetal echocardiography is indicated if there is suspected fetal dysrhythmia or myocarditis, especially in the context of positive maternal anti-Ro/SSA or anti-La/SSB antibodies. Other tests (electrocardiogram plus Holter monitor, magnetocardiography, gated-pulse Doppler technique, velocity-based fetal kinecardiogram) might detect subtle signs of the development of congenital heart block (CHB), but are not currently recommended as standard practice.98 CHB associated with anti-Ro/SSA and/or anti-La/SSB has 16% recurrence rate in women with a previously affected child; therefore, it is recommended to perform serial fetal echocardiograms weekly from 16 weeks of gestation onwards.99 Considering the low risk (0.7–2%) for CHB in women with no previous CHB, it is unclear whether intensive monitoring (weekly/biweekly between 16 and 26 weeks of gestation and less frequently afterwards)98 in the general population of anti-Ro/La-positive women is cost-effective. Moreover, there is no proven efficacy of protocols for the prevention or treatment of complete CHB.98–101 The efficacy of maternal fluorinated steroids has not been established in large cohorts101–104 despite initial reports of favourable effects in cases of incomplete CHB, cardiomyopathy, endocardial fibroelastosis and hydrops fetalis.99 Given the potential of fluorinated steroids for major maternal and fetal side effects, the benefit for fetuses with CHB should be stratified according to the presence of risk factors for adverse outcome.99 Despite its unproven benefit, the current practice of intensive surveillance for CHB onset in women with positive anti-Ro/SSA and/or anti-La/SSB antibodies and no previous child affected by CHB carries no risk and is well accepted by the mothers.105

Drugs for prevention and management of SLE flares during pregnancy

A single randomised, placebo-controlled study60 as well as non-randomised evidence44 15 56 supports the beneficial role of HCQ in controlling disease activity and preventing flare-ups during pregnancy. Uncontrolled studies suggest an acceptable benefit/risk ratio of oral glucocorticoids,12 126 azathioprine50 107 and calcineurin inhibitors (ciclosporin A, tacrolimus)108 109 in controlling SLE activity during pregnancy. In moderate-to-severe flares, additional modalities can be considered, such as high-dose glucocorticoids (including pulse intravenous therapy),110 111 intravenous immunoglobulin20 22 and plasmapheresis (may be also used in refractory nephrotic syndrome).112 113 CYC should not be administered during the first trimester of pregnancy due to risk for fetal loss (OR 25.5)114 and should be reserved only for the management of severe, life-threatening or refractory SLE manifestations during the second or third trimester. Available data are not sufficient to evaluate the risk of using belimumab in pregnancy115 and the drug should not be used unless the benefit outweighs the risk to the fetus. Mycophenolic acid, methotrexate and leflunomide should be avoided due to known or possible teratogenicity.116 To this end, collaborative groups have developed recommendations for the use of antirheumatic drugs before and during pregnancy and lactation.111 117 118

Adjunct treatment during pregnancy

Use of HCQ is recommended in women with SLE preconceptionally and throughout pregnancy.33 56 60 A beneficial role has also been suggested for APS pregnancies,119–121 but at present there is insufficient data to recommend its routine use in these patients. HCQ may reduce the odds of CHB occurrence in fetuses exposed to maternal anti-Ro/SSA antibodies, especially in mothers who already had a child with CHB.40 122

The protective role of LDA against preterm and severe pre-eclampsia has been established in non-autoimmune patients.123 124 Accordingly, women with SLE at higher risk of pre-eclampsia including those with lupus nephritis or positive aPL will benefit from LDA, preferably given preconceptionally or no later than gestational week 16.123 124

In women with definite obstetric APS, combination treatment with LDA and heparin is recommended to decrease the risk of adverse pregnancy outcomes.16 125–127 Statistically significant results have been demonstrated only for unfractionated heparin in RCTs. However, LMWH is preferable for practical reasons and has shown comparable efficacy in prospective studies.128 129 Moreover, patients with positive aPL but with no definite classification of APS will benefit from combination therapy if they are considered at moderate to high risk of maternal and fetal complications (see online supplementary table S5).

In addition, other regimens such as prednisolone 10 mg/day in the first trimester, intravenous immunoglobulin or plasmapheresis can be considered for selected patients with APS (refractory obstetric APS, women with previous thrombosis, particularly previous or new cerebrovascular events, women with triple aPL positivity).119 130–133
Menopause and hormone replacement therapy

The efficacy and safety of hormone replacement therapy (HRT) (oestrogen plus progestin) in selected patients with SLE has been illustrated in RCTs.\(^{134-136}\) Benefit was demonstrated mainly in vasomotor and other hypoestrogenism symptoms. No significantly increased risk of severe lupus exacerbations during 12–24 months of HRT was found, although there was a modest increase in mild-to-moderate flares.\(^{132}\) There was no increased risk of thrombosis and cardiovascular events, although one of the RCTs included only patients with negative aPL and no previous cardiovascular events\(^{132}\) and another did not detail the aPL.

Hydroxychloroquine is beneficial during pregnancy to reduce the risk of SLE flares and of poor obstetrical outcomes. More data are needed to support its benefit in APS pregnancies.

The benefits of cancer surveillance and prevention of gynaecological malignancies need to be communicated to patients.

As recommended in the general population, supplementation with calcium, vitamin D and folic acid should be offered to patients with SLE and/or APS, with particular consideration to those with low circulating levels of 25-OH vitamin D in the first trimester of gestation and receiving glucocorticoids and/or heparin for their detrimental effects on bone mass.

HRT, it seems reasonable to start it as early as possible to gain an added benefit for bone protection.\(^{139}\) Optimal duration of HRT in patients with SLE and/or APS is not known, but it seems reasonable to recommend it for the shortest possible duration.\(^{140,141}\)

Screening for malignancies

Women with SLE are not at increased risk of breast, ovarian and endometrial cancer compared with the general population,\(^{142,143}\) and, therefore, should follow the current population screening protocols for these malignancies. Conversely, women with SLE are at higher risk of cervical dysplasia (but not cervical cancer),\(^{144-147}\) vagina and vulva cancers,\(^{142,144}\) likely associated with human papillomavirus (HPV) infection. Women with SLE exposed to immunosuppressive drugs, particularly CYC in a cumulative dose-dependent fashion, are at higher risk of cervical dysplasia.\(^{148-151}\) The suggested timing for Papanicolaou (PAP) smear examination would be once a year in heavily immunosuppressed patients or according to the local screening programme in low-risk patients. Subgroups of women with SLE (Caucasian, younger age, lower education, high SLE damage) may be at risk for poorer adherence to screening programmes.\(^{152,153}\)

HPV vaccination

HPV vaccination is currently offered to female and male adolescents for preventing precancerous growths and cancer in the cervix and in the genital area. There are reports of venous thromboembolic events (VTEs) associated with the quadrivalent HPV vaccine. However, of the 31 cases (0.2/100 000 doses vaccine) with documented VTE, 90% had a known risk factor for VTE (APS in two cases).\(^{154}\)

Prospective studies have demonstrated efficacy and safety of HPV vaccination in patients with SLE,\(^{155,156}\) although seroconversion rates may be lower in patients receiving steroids and immunosuppressive agents. A few cases of severe SLE flares or abrupt SLE onset after HPV vaccination have been reported.\(^{157-159}\) In accordance with the EULAR recommendations,\(^{160}\) we recommend that HPV vaccination be offered to young women with stable/inactive SLE and/or APS, according to local protocols, with particular caution in those with high-risk aPL profile.

The points to consider and the research agenda suggested by the Task Force Members are reported in box 2.

### Recommendations

As required, the points to consider and research agenda suggested by the Task Force Members are reported in box 2.
Recommendations

1. Unit of Obstetrics and Gynaecology, Spedali Civili, Brescia, Italy
2. EULAR PARE Patient Research Partner, Rome, Italy
3. Department of Clinical Sciences and Community Health, University of Milan, Istituto Auxologico Italiano, Milan, Italy
4. Rheumatology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
5. Neonatology and Neonatal Intensive Care Unit, Spedali Civili, Brescia, Italy
6. Norwegian National Advisory Unit on Pregnancy and Rheumatic Diseases, St. Olavs Hospital, Trondheim University Hospital, Trondheim, Norway
7. Department of Rheumatology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj-Napoca, Romania
8. Department of Obstetrics and Gynaecology, University Hospital of Bern, Inselspital, Switzerland
9. Rheumatology Unit, Department of Medicine, Solna, Karolinska Institutet, Karolinska University Hospital, Stockholm, Sweden
10. Rheumatology Unit, Joint Academic Rheumatology Programme, 1st Department of Propaedeutic Internal Medicine Athens, National and Kapodistrian University of Athens, Athens, Greece
11. Department of Rheumatology, Istanbul Bilim University, Istanbul Florence Nightingale Hospital, Esentepe-Istanbul, Turkey
12. 4th Department of Internal Medicine, ‘Attkon’ University Hospital, Medical School, University of Athens, Athens, Greece
13. Joint Academic Rheumatology Program, National and Kapodistrian University of Athens, Athens, Greece

Acknowledgements

The committee wishes to acknowledge the support of the EULAR Standing Committee on Clinical Affairs. The committee also expresses its sincere appreciation and gratitude to the EULAR Secretariat and especially to Patrizia Jud, executive assistant, for outstanding organisation.

Contributors

La and GKB contributed equally to the article. DB and AT share senior authorship. All the authors contributed to discussion of the results of the systematic literature review (performed by LA and GKB) and to the review of the article.

Competing interests

None declared.

Provenance and peer review

Not commissioned; externally peer reviewed.

Open Access

This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

REFERENCES

18. Izmirli PM, Costedoat-Chalumeau N, Pisoni CN, et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent s-SSA/
Recommendations


132 Alfi et al. 2015;351:h5746.


